Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis

European Heart Journal

Volumn 26, Issue 21, 2005, Pages 2294-2299

  Speidl, Walter S ^a,b   Exner, Markus ^a   Amighi, Jasmin ^a   Kastl, Stefan P ^a,b   Zorn, Gerlinde ^a,b   Maurer, Gerald ^a,b   Wagner, Oswald ^a   Huber, Kurt ^c   Minar, Erich ^a   Wojta, Johann ^a,b   Schillinger, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c Wilhelminenhospital   (Austria)

Author keywords

Atherosclerosis; Complement factor; Complications; Inflammation

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C5A; FIBRINOGEN; SERUM AMYLOID A;

ADULT; AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY SURGERY; COMPLEMENT SYSTEM; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; DEATH; DISEASE COURSE; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROSURGERY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 27544498810     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi339     Document Type: Article

References (32)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340(2):115-126.
2. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101(18):2149-2153.
3. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107(5):690-695.
4. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351(9096):88-92.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336(14):973-979.
6. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, Wojta J, Huber K. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002;144(3):449-455.
7. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, Wagner O, Minar E. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003;108(19):2323-2328.
8. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999;36(13-14):949-955.
9. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985;57(2-3):163-177.
10. Laine P, Pentikainen MO, Wurzner R, Penttila A, Paavonen T, Meri S, Kovanen PT. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002;90(4):404-408.
11. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158(3):1039-1051.
12. Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988;81(3):918-923.
13. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999;162(7):4018-4023.
14. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994;94(3):1147-1155.
15. Okusawa S, Yancey KB, van der Meer JW, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 1988;168(1):443-448.
16. Muscari A, Bozzoli C, Gerratana C, Zaca F, Rovinetti C, Zauli D, La Placa M, Puddu P. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis 1988;74(1-2):179-186.
17. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000;21(13):1081-1090.
18. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995;98(4):357-364.
19. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000;31(1):S1-S296.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36(3):959-969.
21. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20(7):864-870.
22. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997;77(2):394-398.
23. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14(1):32-40.
24. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, Suriyaphol P, Han SR, Lckner KJ, Husmann M. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004;109(15):1870-1876.
25. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990;172(2):547-557.
26. Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003;14(5):477-482.
27. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344(15):1140-1144.
28. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004;93(2):198-200.
29. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107(9): 1303-1307.
30. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Nicolau JC, Ruzyllo W, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108(10):1184-1190.
31. Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004;291(19):2319-2327.
32. Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004;77(3):942-949 (discussion 949-950).